Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Copper chloride is an inorganic small molecule being developed as a research-stage intrauterine formulation for the treatment of infertility. Specifically, it is investigated for patients with suboptimal endometrial thickness and recurrent implantation failure. The drug is delivered as a micro-dose of copper chloride (CuCl2) suspended in an inert carrier gel and applied directly into the uterine cavity. Its primary mechanism of action involves stimulating the production of vascular endothelial growth factor (VEGF) within the endometrium, which promotes angiogenesis and increases endometrial thickness to improve the environment for embryo implantation. It has been evaluated in the NuLIFE clinical trial led by researchers at Flinders University.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on copper chloride.